Skip to content
lifestyle.washingtonguardian.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Immutep Limited
TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis
March 13, 2026
Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
February 10, 2026
Immutep Quarterly Activities Report Q2 FY26
January 29, 2026
←
Previous Page
1
2